샘플 요청 목록

 카트 문의
시장보고서
상품코드
1757595

세계의 전두측두엽 치매(FTD) 시장

Frontotemporal Dementia
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 381 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 전두측두엽 치매(FTD) 시장은 2030년까지 3억 6,640만 달러에 달할 전망

2024년에 2억 6,510만 달러로 추정되는 세계의 전두측두엽 치매(FTD) 시장은 2024-2030년에 CAGR 5.5%로 성장하며, 2030년에는 3억 6,640만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 인지 기능 강화제는 CAGR 6.6%를 기록하며, 분석 기간 종료시에는 1억 2,600만 달러에 달할 것으로 예측됩니다. 항정신병약 부문의 성장률은 분석 기간 중 CAGR 6.4%로 추정됩니다.

미국 시장은 7,220만 달러로 추정, 중국은 CAGR 8.9%로 성장 예측

미국의 전두측두엽 치매(FTD) 시장은 2024년에 7,220만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 8.9%로 추이하며, 2030년에는 예측 시장 규모 7,440만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.6%와 5.5%로 예측됩니다. 유럽에서는 독일이 CAGR 3.6%로 성장할 것으로 예측됩니다.

세계의 전두측두엽 치매(FTD) 시장 - 주요 동향과 촉진요인 정리

전두측두엽 치매(FTD)가 임상과 연구에서 주목받는 이유

전두측두엽 치매(FTD)는 조기 발병, 복잡한 증상, 제한된 치료 옵션으로 인해 신경 퇴행성 질환 연구에서 중요한 관심 분야로 부상하고 있습니다. 주로 기억력에 영향을 미치는 알츠하이머병과 달리 FTD는 보통 45-65세 사이에 발병하며, 성격, 행동, 언어에 심각한 변화를 가져옵니다. 비알츠하이머형 치매에 대한 인식이 높아지면서 임상의들은 FTD를 행동변형 FTD(bvFTD)와 1차성 진행성 실어증(PPA)과 같은 고유한 병리학적 아형을 가진 별도의 진단 대상으로 인식하고 있습니다.

FTD는 정신질환이나 야행성 우울증으로 오진되는 경우가 많기 때문에 다른 신경질환이나 정신질환과 구분할 수 있는 바이오마커 기반의 진단 툴와 영상 진단이 절실히 요구되고 있습니다. 이러한 개발로 인해 제약 및 진단 제약사들은 아직 충분히 서비스되지 않고 빠르게 성장하고 있는 이 질환 분야에서 혁신을 일으킬 수 있는 기회를 얻게 되었습니다.

진단과 치료의 혁신이 질병 관리를 어떻게 변화시킬 것인가?

신경영상, 유전체학, 분자병리학의 발전으로 전두측두엽 치매(FTD)의 진단 정확도와 조기 발견이 향상되고 있으며, PET 및 MRI 영상 진단 기술은 뇌의 국소적 위축을 확인하기 위해 개선되고 있고, 뇌척수액(CSF) 바이오마커와 유전자 프로파일링은 FTD와 알츠하이머병 및 기타 신경퇴행성 질환을 구별할 수 있게 해줍니다. 타우 단백질이나 TDP-43 단백질과 같은 바이오마커의 출현은 FTD 치료에 있으며, 정밀의료 접근법의 길을 열어주고 있습니다.

치료 측면에서는 대증요법에서 질병을 조절하는 타겟으로 연구가 이동하고 있습니다. RNA 기반 치료제, 항센스 올리고뉴클레오티드(ASO), 타우 응집 억제제 등이 임상시험에 진입하고 있으며, 질병의 진행을 늦추거나 멈추게 하는 것을 목표로 하고 있습니다. 이와 함께 이 질병에 수반되는 인지적, 정서적 증상을 관리하기 위한 디지털 치료제와 행동 중재가 개발되고 있습니다. 이러한 기술 혁신은 FTD의 임상적, 상업적 접근 방식에 대한 패러다임 전환의 발판을 마련하고 있습니다.

표적형 FTD 솔루션의 추진을 촉진하는 이해관계자는 누구인가?

전두측두엽 치매(FTD)를 둘러싼 생태계는 학계 연구자, 생명공학 기업, 환자 옹호 단체, 의료 규제 당국의 참여가 증가하고 있습니다. 희귀질환 프레임워크와 희귀질환 치료제 정책은 상대적으로 유병률이 낮지만 부담이 큰 이 분야의 혁신을 지원하고 있습니다. 환자 등록 및 종단적 관찰 연구는 질병 진행을 이해하고, 임상시험 설계를 촉진하며, 초기 바이오마커를 식별하는 데 도움이 되는 귀중한 데이터를 제공합니다.

제약사들은 FTD의 미충족 의료 수요를 인식하고 알츠하이머병과 파킨슨병 연구를 중심으로 구축된 신경퇴행성 연구개발 플랫폼을 활용하여 FTD 적응증으로 축을 옮기고 있습니다. 벤처캐피털의 자금 지원과 공동 컨소시엄도 틈새 신경 영역의 선두를 노리는 FTD 전문 바이오텍에 유입되고 있습니다. 디지털 진단과 원격 인지기능 평가의 역할이 증가하면서 환자 모니터링의 분산화와 초기 단계 및 지방 환자들에 대한 치료 접근성이 확대되고 있습니다.

전두측두엽 치매(FTD) 시장의 성장을 가속하는 주요 요인은?

전두측두엽 치매(FTD) 시장의 성장은 진단 기술 혁신, 임상 연구 모멘텀, 정밀 신경학의 부상과 관련된 몇 가지 요인으로 인해 발생합니다. 가장 강력한 촉진요인 중 하나는 FTD가 명확하고 과소 진단된 질환이라는 인식이 높아지면서 첨단 신경 영상, 유전자 검사, AI 기반 진단 플랫폼에 대한 수요가 증가하고 있다는 점입니다. 전 세계에서 조기발병형 치매의 유병률이 증가함에 따라 정확하고 시기적절한 진단과 맞춤 치료 경로에 대한 대응 요구가 증가하고 있습니다.

또 다른 중요한 원동력은 FTD의 병태와 겹치는 신경퇴행성 단백질 질환, 특히 타우병에 초점을 맞춘 의약품의 연구개발이 급증하고 있다는 점입니다. 희귀질환 의약품에 대한 우대 조치, 규제 당국의 신속한 지정, 민관 연구 파트너십의 확대는 FTD를 표적으로 하는 치료법 개발을 가속화하고 있습니다. 또한 현역 세대에서 FTD의 정신적, 경제적 부담은 지불자와 정책 입안자들이 조기 개입 전략과 지원 서비스의 우선순위를 정하도록 유도하고 있습니다. 이러한 역학이 맞물리면서 시장 역학은 신경학 분야에서 큰 영향력을 가진 성장 프론티어로서 자리매김하고 있습니다.

부문

약제 클래스(인지 기능 강화약, 항정신병약, 항우울제, 중추 신경 자극약, 기타 약제 클래스별); 질환 적응증(전두측두엽 치매(FTD), 원발성 진행성 실어증, 운동장애); 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업의 예(합계 42사)

  • Alector Inc.
  • Allergan plc
  • Apotex Inc.
  • Asceneuron SA
  • AstraZeneca plc
  • AviadoBio Ltd.
  • Biogen Inc.
  • CervoMed Inc.
  • Denali Therapeutics Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Passage Bio, Inc.
  • Pfizer Inc.
  • Prevail Therapeutics
  • Sanofi S.A.
  • Wave Life Sciences Ltd.

AI 통합

우리는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유 SLM을 조회하는 일반적인 규범을 따르는 대신에 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.08

Global Frontotemporal Dementia Market to Reach US$366.4 Million by 2030

The global market for Frontotemporal Dementia estimated at US$265.1 Million in the year 2024, is expected to reach US$366.4 Million by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Cognitive Enhancers, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$126.0 Million by the end of the analysis period. Growth in the Antipsychotics segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$72.2 Million While China is Forecast to Grow at 8.9% CAGR

The Frontotemporal Dementia market in the U.S. is estimated at US$72.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$74.4 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Frontotemporal Dementia Market - Key Trends & Drivers Summarized

Why Is Frontotemporal Dementia Gaining Increasing Clinical and Research Attention?

Frontotemporal dementia (FTD) is emerging as a critical focus area in neurodegenerative disease research due to its early onset, complex symptomatology, and limited treatment options. Unlike Alzheimer’s disease, which primarily affects memory, FTD leads to significant changes in personality, behavior, and language at an earlier age-typically between 45 and 65 years. As awareness of non-Alzheimer’s dementias rises, clinicians are increasingly recognizing FTD as a distinct diagnostic entity with its own set of pathological subtypes, including behavioral variant FTD (bvFTD) and primary progressive aphasia (PPA).

The growing burden of FTD is prompting urgent calls for better diagnostic frameworks, caregiver support, and disease-modifying therapies. Because FTD is often misdiagnosed as psychiatric illness or late-onset depression, there is a strong push toward biomarker-based tools and imaging diagnostics that can differentiate FTD from other neurological or psychiatric disorders. These developments are creating opportunities for pharmaceutical and diagnostic companies to innovate within this underserved but rapidly expanding disease segment.

How Are Diagnostic and Therapeutic Innovations Transforming Disease Management?

Advancements in neuroimaging, genomics, and molecular pathology are enhancing the diagnostic accuracy and early detection of frontotemporal dementia. PET and MRI imaging techniques are being refined to identify regional brain atrophy, while cerebrospinal fluid (CSF) biomarkers and genetic profiling are enabling differentiation of FTD from Alzheimer's and other neurodegenerative conditions. The emergence of biomarkers such as tau and TDP-43 proteins is opening pathways for precision medicine approaches in FTD care.

On the therapeutic front, research is shifting from symptomatic relief toward disease-modifying targets. Pipeline therapies are exploring mechanisms that address underlying proteinopathies, neuroinflammation, and synaptic dysfunction. RNA-based therapies, antisense oligonucleotides (ASOs), and tau aggregation inhibitors are entering clinical trials, aiming to slow or halt disease progression. In parallel, digital therapeutics and behavioral interventions are being developed to manage the cognitive and emotional symptoms associated with the disease. These innovations are setting the stage for a paradigm shift in how FTD is approached both clinically and commercially.

Which Stakeholders Are Driving the Push for Targeted FTD Solutions?

The ecosystem surrounding frontotemporal dementia is witnessing increased engagement from academic researchers, biotech firms, patient advocacy groups, and health regulators. Rare disease frameworks and orphan drug policies are supporting innovation in this relatively low-prevalence yet high-burden segment. Patient registries and longitudinal observational studies are supplying valuable data to aid in understanding disease progression, facilitating clinical trial design, and identifying early biomarkers.

Pharmaceutical companies are recognizing the unmet medical need in FTD and leveraging their neurodegeneration R&D platforms-often built around Alzheimer’s and Parkinson’s research-to pivot into FTD indications. Venture capital funding and collaborative consortia are also flowing into FTD-focused biotechs aiming to lead in niche neurology. The increasing role of digital diagnostics and remote cognitive assessments is further enabling decentralized patient monitoring, widening access to care for individuals in early-stage or rural settings.

What Are the Primary Drivers Fueling Growth in the Frontotemporal Dementia Market?

The growth in the frontotemporal dementia market is driven by several factors related to diagnostic innovation, clinical research momentum, and the rise of precision neurology. One of the most powerful growth drivers is the increasing recognition of FTD as a distinct and underdiagnosed condition, which is spurring demand for advanced neuroimaging, genetic testing, and AI-based diagnostic platforms. As the prevalence of early-onset dementias rises globally, there is a corresponding need for accurate, timely diagnosis and personalized care pathways.

Another key driver is the surge in pharmaceutical R&D focused on neurodegenerative proteinopathies, especially tauopathies, which overlap with FTD pathogenesis. The availability of orphan drug incentives, fast-track regulatory designations, and growing public-private research partnerships are accelerating the development of FTD-targeted treatments. Additionally, the emotional and economic burden of FTD on working-age populations is prompting payers and policymakers to prioritize early intervention strategies and support services. These intersecting dynamics are positioning the frontotemporal dementia market as a high-impact growth frontier in neurology.

SCOPE OF STUDY:

The report analyzes the Frontotemporal Dementia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Other Drug Classes); Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, Movement Disorders); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Alector Inc.
  • Allergan plc
  • Apotex Inc.
  • Asceneuron SA
  • AstraZeneca plc
  • AviadoBio Ltd.
  • Biogen Inc.
  • CervoMed Inc.
  • Denali Therapeutics Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Passage Bio, Inc.
  • Pfizer Inc.
  • Prevail Therapeutics
  • Sanofi S.A.
  • Wave Life Sciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Frontotemporal Dementia - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Population Propels Demand for Specialized Dementia Treatments
    • Advancements in Genetic Research Enhance Understanding of Disease Mechanisms
    • Increased Awareness and Early Diagnosis Initiatives Drive Market Growth
    • Development of Precision Medicine Strengthens Personalized Treatment Approaches
    • Rising Investment in Neurodegenerative Disease Research Fuels Therapeutic Innovations
    • Integration of AI and Telemedicine Improves Patient Monitoring and Care
    • Emergence of Biomarker-Based Diagnostics Enhances Early Detection Capabilities
    • Growing Demand for Non-Pharmacologic Therapies Supports Market Diversification
    • Implementation of Dementia-Friendly Community Programs Encourages Social Inclusion
    • Expansion of Caregiver Support Services Addresses Increasing Care Demands
    • Adoption of Digital Health Records Improves Data Sharing and Patient Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Frontotemporal Dementia Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cognitive Enhancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cognitive Enhancers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Cognitive Enhancers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for CNS Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for CNS Stimulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for CNS Stimulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Primary Progressive Aphasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Primary Progressive Aphasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Primary Progressive Aphasia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Movement Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Movement Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Movement Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • JAPAN
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • CHINA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • EUROPE
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Frontotemporal Dementia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • FRANCE
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • GERMANY
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Frontotemporal Dementia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • INDIA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Frontotemporal Dementia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Frontotemporal Dementia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030
  • AFRICA
    • Frontotemporal Dementia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Frontotemporal Dementia by Drug Class - Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Frontotemporal Dementia by Drug Class - Percentage Breakdown of Value Sales for Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Frontotemporal Dementia by Distribution Channel - Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Frontotemporal Dementia by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Distribution Channel and Hospital Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Frontotemporal Dementia by Disease Indication - Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Frontotemporal Dementia by Disease Indication - Percentage Breakdown of Value Sales for Frontotemporal Dementia, Primary Progressive Aphasia and Movement Disorders for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제